Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval

Pfizer and German partner Merck KGaA's Bavencio secures an EU approval for metastatic Merkel cell carcinoma. The company also expects to make the drug commercially available within a month.

AZN : 33.95 (+3.47%)
MRK : 65.13 (-0.72%)
KITE : 179.30 (-0.04%)
PFE : 35.96 (-0.03%)
Dow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in Bill.com

The Dow mopped up gains over the week, buoyed by announcements from the Federal Reserve.

AAPL : 151.89 (-0.98%)
JPM : 94.83 (-0.21%)
JNJ : 131.39 (-0.27%)
MRK : 65.13 (-0.72%)
PG : 92.24 (-0.43%)
FB : 170.54 (-0.33%)
PFE : 35.96 (-0.03%)
BA : 256.45 (+0.16%)
Cancer Space Update: Mixed Week for Pfizer, Roche Falters

Roche again disappointed this week with two studies on Tecentriq being put on partial hold while Pfizer's Bavencio received approval in Europe. TESARO's Zejula moved a step closer to approval.

MRK : 65.13 (-0.72%)
KPTI : 10.63 (+1.43%)
TSRO : 119.04 (+0.31%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update

Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.

JNJ : 131.39 (-0.27%)
SUPN : 39.00 (-1.02%)
TEVA : 17.19 (+0.23%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
GSK : 40.58 (+0.62%)
BMY : 63.36 (+0.05%)
National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views

Pfizer Inc. (NYSE:PFE), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results from a new national poll designed to deepen understanding...

PFE : 35.96 (-0.03%)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a discussion with Liz Barrett, Global President, Oncology, and Chris Boshoff, Senior Vice President and Head, Immuno-Oncology,...

PFE : 35.96 (-0.03%)
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake

Pfizer (PFE) filed a lawsuit in a U.S. district court alleging that J&J is resorting to anticompetitive practices to prevent uptake of Inflectra.

JNJ : 131.39 (-0.27%)
MRK : 65.13 (-0.72%)
AMGN : 185.76 (-0.47%)
PFE : 35.96 (-0.03%)
Stock Market News For Sep 21, 2017

Markets closed mostly higher on Wednesday after the Federal Reserve announced trimming of its balance sheet from October.

C : 71.40 (-0.50%)
PNC : 133.43 (+0.06%)
BAC : 25.02 (-0.56%)
JPM : 94.83 (-0.21%)
GS : 231.03 (-0.11%)
PFE : 35.96 (-0.03%)
MCD : 158.91 (-0.08%)
National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views

NEW YORK , Sept. 21, 2017 /PRNewswire-USNewswire/ -- Pfizer Inc. (NYSE:PFE), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results...

PFE : 35.96 (-0.03%)
National Sickle Cell Disease Poll of African Americans Dispels Long-Held Views

Pfizer Inc. (NYSE:PFE), the National Newspaper Publishers Association (NNPA), and scholars from Howard University today announced results from a new national poll designed to deepen understanding and gauge...

PFE : 35.96 (-0.03%)
Can Pfizer (PFE) Prove to be an Apt Value Investment?

Let's find out if Pfizer, Inc. (PFE) stock is a good choice for value-oriented investors right now

PFE : 35.96 (-0.03%)
New Global Report Finds Majority of People at High Risk of Stroke Not Being Screened for Common Risk Factors

New research released today by The Economist Intelligence Unit (EIU), a division of The Economist and a leader in global business intelligence, revealed that on average, more than 75 percent...

PFE : 35.96 (-0.03%)
BMY : 63.36 (+0.05%)
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

DARMSTADT, Germany and NEW YORK, USA , September 21, 2017 /PRNewswire/ --

MRK : 65.13 (-0.72%)
PFE : 35.96 (-0.03%)
MKKGY : 23.0900 (+0.26%)
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma

Not intended for UK-based media

PFE : 35.96 (-0.03%)
Mylan Down 24% Year to Date: What's Troubling the Stock?

Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.

MYL : 31.30 (+0.19%)
NVS : 86.16 (+1.44%)
RHHBY : 32.0200 (-0.06%)
PFE : 35.96 (-0.03%)
Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View

Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.

BAYRY : 33.0300 (-0.09%)
NVO : 49.22 (+0.33%)
NVS : 86.16 (+1.44%)
PFE : 35.96 (-0.03%)
Pfizer Goes to Court to Allow Competition for Biologics and Expand Options for Patients

To ensure patients and providers have access to important, lower cost biosimilar medicines, Pfizer (NYSE:PFE) today filed suit in the U.S. District Court for the Eastern District of Pennsylvania...

PFE : 35.96 (-0.03%)
Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT(R) in Patients at High Risk of Recurrent Renal Cell Carcinoma after Surgery

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drug Advisory Committee (ODAC) voted 6 in favor and 6 against the benefit-risk profile...

PFE : 35.96 (-0.03%)
Pfizer Invites Public to View and Listen to Webcast of October 31 Conference Call with Analysts

Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Tuesday, October 31, 2017. The purpose...

PFE : 35.96 (-0.03%)
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates

: Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.

JNJ : 131.39 (-0.27%)
NVS : 86.16 (+1.44%)
CPRX : 2.44 (unch)
PFE : 35.96 (-0.03%)

Van Meerten Stock Picks

5 Great Mid Caps
Today I wanted to find 5 Mid Cap stocks that had a high gain over the last year and continue to have current momentum.
DAN +0.41 , IPGP +4.16 , TEX -0.46 , NVR +29.06 , TTWO +1.12
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Dec E-mini S&Ps ( ESZ17 -0.14% ) this morning are down -0.09% on heightened North Korean tensions after North Korean President Kim Jong Un promised the "highest level of hardline" countermeasures against the U.S.... Read More

Chart of the Day

Chart of the Day

Fiat Chrysler Automobiles (FCAU) is the Barchart Chart of the Day.  The international auto producer has a Trend Spotter buy signal, a Weighted Alpha of 190.70+ and gained 174.92% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures settled Friday with 2 to 3 1/2 cent gains, as Dec was 1 1/4 cent lower on the week. Rains over the next week could slow corn harvest in most of the WCB. Next Friday at 11:00 a.m. will be the release of the Sept 1 Grain Stocks report. The...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.